Conavi Medical Corp
- LAST PRICE0.8400
- TODAY'S CHANGE (%)-0.0500 (-5.6180%)
- Bid / Lots0.8300/ 5
- Ask / Lots0.9000/ 26
- Open / Previous Close0.8500 / 0.8900
- Day Range
- 52 Week Range
- Volume12,784
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CNVI |
|---|---|---|
| 10:56 ET | 11500 | 0.85 |
| 11:41 ET | 1000 | 0.84 |
Oct 28, 2024
JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies, from 8:15AM ET on Monday Oct 28, 2024 by Dow Jones
8:15AM ET on Monday Oct 28, 2024 by Dow Jones
Oct 22, 2024
Conavi Medical Corp. Engages ICP Securities Inc. for Automated Market Making Services, from 4:45PM ET on Tuesday Oct 22, 2024 by Dow Jones
4:45PM ET on Tuesday Oct 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Conavi Medical Corp | 39.4M | -13.6x | --- |
Nanalysis Scientific Corp | 41.3M | -2.9x | --- |
Kovo+Holdings Inc | 8.0M | -0.5x | --- |
Hydreight Technologies Inc | 31.4M | -18.9x | --- |
MedMira Inc | 57.7M | -16.9x | --- |
Theralase Technologies Inc | 63.6M | -14.9x | --- |
Company Information
Conavi Medical Corp., formerly Titan Medical Inc., is a Canada-based company. The Company is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The Novasight Hybrid System is intended for intravascular imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. Its Novasight Hybrid System combines both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. Hybrid IVUS and OCT imaging provides additional information over single modality imaging in complex lesions. The versatility of hybrid imaging is useful for a variety of complex percutaneous coronary intervention (PCIs), including situations where the customer may want to image large ostial lesions with IVUS but also use OCT for diseased distal lesions and/or stent assessment.
Contact Information
- Headquarters
- 76 Berkeley StreetTORONTO, ON, Canada M5A 2W7
- Phone
- 416-548-7522
- Fax
- 416-548-7522
Executives
- Chief Executive Officer, Director
- Thomas Looby
- Chief Financial Officer
- Stefano Picone
- Director
- Susan Allen
- Director
- Aaron Davidson
- Director
- Robert Mitchell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $39.4M |
|---|---|
Revenue (TTM) | $1.3M |
Shares Outstanding | 44.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.76 |
EPS | $-0.06 |
Book Value | $0.06 |
P/E Ratio | -13.6x |
Price/Sales (TTM) | 29.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -604.84% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
